AstraZeneca Reports Q1 2024 Revenue of $12.68 Billion, China Sales Reach $1.75 Billion with Enhertu Surging 79% Year-over-Year
AstraZeneca
Biopharmaceutical Manufacturer
On April 25, AstraZeneca announced its Q1 2024 performance, achievingRevenue 12.679 billionUSD, fixedExchange Rate (CER, hereinafter the same)Up 19% Year on Year。
Source: AstraZeneca Financial Report ((The following text is from the same source unless otherwise noted.)
China remains one of the core regions for AZ's efforts.Q1 Achieves $1.748 Billion in Revenue, representing a year-on-year increase of 13%, with outstanding performance in emerging markets.
From the TOP10 products,Dapagliflozin Surpasses Osimertinib to Top AZ Sales with $1.892 Billion in Revenue, increasing by 45% year-on-year.Osimertinib grew steadily by 15% to $1.595 billion;PD-L1 monoclonal antibody durvalumab also increased by 33% year-over-year, achieving single-quarter sales of $1.113 billion.
In addition to the above TOP3 flagship products, the rare disease pipelineUltomirisThe upward trend is also not to be underestimated, this isEculizumab (Soliris)The next-generation successor product is accelerating patient penetration by leveraging the company's established advantages in the rare disease field, with Q1 growth exceeding 30%. BTK inhibitorAcalabrutinib (Calquence)Also on the rise, with a year-on-year increase of 35%, competing for the top position in the same field as Johnson & Johnson's Ibrutinib.
In addition, Enhertu successfully entered the TOP10 list,Sales increased by 79% year-on-year to reach 461 million US dollars；Including the sales of Daiichi Sankyo, a total revenue of 879 million US dollars was achieved., representing a year-over-year increase of 65.5% (Q1 2023 sales were $531 million). Of this, sales in the U.S. region amounted to $423 million (Q1 2023: $336 million).
AstraZeneca TOP10 Sales Products in Q1 2024
AstraZeneca is also accelerating the clinical progress of other high-value pipelines:
Cover Source:Company Logo
Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If you have any needs, please consult and contact正规医疗机构.
Editor：Hebe
PR Article Coordination: WeChat insightxb
SubmissionWeChat: insightxb; Email: insight@dxy.cn
Diversified functions, traceable data……
Insight Database Web Version Awaits Your Experience
Click to read the original text,ImmediatelyUnlock！
